Arjona Ferreira Juan Camilo 4

What Happened Juan Camilo Arjona, Organon & Co.'s Head of R&D and Chief Medical Officer, had RSUs convert into 8,865 shares on March 29, 2026 (reported on Form 4 filed 2026-03-31). The RSUs converted at no exercise price (reported $0.00). To satisfy tax withholding, 3,181 of those shares were withheld (disposition) at the plan-required price of $5.84 per share, resulting in withholding valued at approximately $18,577.

Key Details

• Transaction date: March 29, 2026; Form 4 filed March 31, 2026 (not a late filing).
• Conversion: 8,865 RSUs converted to shares (derivative exercise/conversion, code M).
• Tax withholding: 3,181 shares withheld (code F) at $5.84/share = $18,577.
• RSU mechanics: Each RSU equals one share (F4); these RSUs vest in three equal installments on 3/29/2025, 3/29/2026 and 3/29/2027 (F5).
• Ownership adjustments: Filing notes beneficial ownership was reduced to reflect a transfer of 13,872 shares under Exchange Act Rule 16a-12 (F1). Also includes 708.122 shares from dividend equivalents net of withholding (F3).
• Price note: $5.84 is the closing market price on March 27, 2026, used by the plan (F2).

Context This was a routine conversion/vesting of RSUs rather than an open-market purchase or sale. The withholding of 3,181 shares to cover taxes is a common cashless-withholding practice and not an active sale by the insider. RSU vesting and related withholdings are part of standard compensation administration and should be viewed as such unless accompanied by separate open-market trades.